Epizyme (EPZM) Commences Dosing in Tazemetostat Phase 2 for Genetically Defined Tumors
Tweet Send to a Friend
Epizyme, Inc. (NASDAQ: EPZM) announced that the first patient has been dosed in the phase 2 study of tazemetostat in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
